Pharmaceutical preparations for the treatment of blood conditions; Pharmaceutical preparations for the treatment of transplant diseases, illnesses, and conditions; Pharmaceutical preparations for renal transplant diseases, illnesses, and conditions; Pharmaceutical preparations for kidney diseases, illnesses and conditions; Pharmaceutical preparations for treatment of antibody mediated rejection in adult renal transplant recipients; pharmaceutical preparations to treat hematology diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of emphysema diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, acute respiratory distress syndrome, ARDS; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions, namely, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Pharmaceuticals